Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Novo Nordisk Foundation Commits DKK 5.5 Billion to the BioInnovation Institute (BII) through 2035
In a strategic move set to reshape the European biotech and science innovation landscape, the Novo Nordisk Foundation has pledged a long-term investment of up to DKK 5.5 billion (≈ €736 million) to the Copenhagen-based BioInnovation Institute (BII), extending support through 2035. This unprecedented investment will expand BII’s role in commercializing science, scaling startups, and building cross-sector bridges across Europe.
The commitment also signals a broader push to close Europe’s long-standing gap between world-class research and global commercial leadership in emerging technologies. [Read more…]
Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture and Commercialize Cytora’s Allogeneic Stem Cell Therapy in U.S.
Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications
PRINCETON, N.J. and DAVIE, Fla. and TEL AVIV, Israel, Jan. 7, 2026 – Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and market access of biologics, today announced a comprehensive strategic partnership to advance and commercialize Cytora’s novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the United States. [Read more…]
Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience
CARLSBAD, Calif. – Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. [Read more…]
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 146
- Next Page »